INS and metabolic syndrome: Although randomized control trials using MYO-INS and/or DCI as supplement gave positive results in improving insulin resistance and reducing cardiovascular risk factors in women with PCOS and gestational diabetes mellitus or metabolic syndrome postmenopause, larger studies including both genders are needed in order to extend a possible application for a more generalized population at risk of developing or already presenting insulin resistance.